Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 19;66(4):e0243221.
doi: 10.1128/aac.02432-21. Epub 2022 Mar 21.

Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021

Tanner E Rothstein  1 , Scott A Cunningham  1 , Rachelle A Rieke  1 , Jill M Mainella  1 , Melissa M Mutchler  1 , Robin Patel  1   2
Affiliations

Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021

Tanner E Rothstein et al. Antimicrob Agents Chemother. .

Abstract

The epidemiology of macrolide resistance in Mycoplasma (Mycoplasmoides) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.

Keywords: Mycoplasma pneumoniae; antibiotic resistance; macrolides; pneumonia; surveillance studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. Dr. Patel reports grants from Merck, ContraFect, TenNor Therapeutics Limited and Shionogi. Dr. Patel is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, and Qvella; monies are paid to Mayo Clinic. Dr. Patel is also a consultant to Netflix. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Scott A. Cunningham reports receiving an honorarium from the Antibacterial Resistance Leadership Group.

Figures

FIG 1
FIG 1
M. pneumoniae ptsI PCR tests performed from January 2014 through November 2021 showing total numbers of monthly tests performed (blue background) and monthly percent positivity (red line). There was typically a rise in positivity in late fall/winter, except for COVID-19 pandemic times and, to some extent, the 2017–2018 season. Between February 2017 and August 2018, the overall positivity rate was 1% (52/6,238). Peak annual positivity rates were observed in December 2014 (4%), November 2015 (4%), January 2016 (3%), June 2017 (2%), October 2018 (3%), and September 2019 (4%). Macrolide resistant isolates were found in 2014 (n = 1), 2015 (n = 3), 2016 (n = 3), and 2019 (n = 4), but notably, not all specimens testing positive for M. pneumoniae were assessed for macrolide resistance.
FIG 2
FIG 2
Geographic locations of patients testing positive for M. pneumoniae. Shown is the total number of positive tests by state. States shown in gray had no positive results; states shown in dark blue or orange had positive results. Macrolide-resistant M. pneumoniae was detected in states shown in orange, with the percentage of macrolide-resistant M. pneumoniae listed below the specimen numbers.
See this image and copyright information in PMC

References

    1. Waites KT-R, et al.. 2011. Mycoplasma and Ureaplasma, p 970–985. In Versalovic J, Carroll KC, Jorgensen JG, Funke G, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.
    1. Jacobs E, Ehrhardt I, Dumke R. 2015. New insights in the outbreak pattern of Mycoplasma pneumoniae. Int J Med Microbiol 305:705–708. 10.1016/j.ijmm.2015.08.021. - DOI - PubMed
    1. Winchell MJ. 2013. Mycoplasma pneumoniae–a national public health perspective. Curr Pediatr Rev 9:324–333. 10.2174/15733963113099990009. - DOI
    1. Waites KB, Ratliff A, Crabb DM, Xiao L, Qin X, Selvarangan R, Tang Y-W, Zheng X, Bard JD, Hong T, Prichard M, Brooks E, Dallas S, Duffy L, Mixon E, Fowler KB, Atkinson TP, Diekema DJ. 2019. Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol 57:e00968-19. 10.1128/JCM.00968-19. - DOI - PMC - PubMed
    1. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. 2017. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev 30:747–809. 10.1128/CMR.00114-16. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources